| Acceptance rate | 46% |
|---|---|
| Time to first decision | 20 days* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2024 , Vol 62 , Num 2
The potential impact of vascular endothelial growth factor rs699947 polymorphisms on breast tumors susceptibility in a sample of Iraqi females
1 Department of Pharmacy, Al-Hilla University College, Babylon, Iraq2 Department of Chemistry and Biochemistry, College of Medicine, Al-Nahrain University, Baghdad, Iraq
3 Department of General Surgery, College of Medicine, Al-Nahrain University, Baghdad, Iraq
DOI : 10.23893/1307-2080.APS6217 The angiogenic factor vascular endothelial growth factor (VEGF) plays a pivotal role in tumor initiation, progression, and metastasis. Polymorphisms in VEGF gene can alter the activity of the gene"s promoter, leading to increased or decreased VEGF secretion. This study aimed to investigate the association of VEGF rs699947 polymorphisms with breast cancer risk in female from Baghdad- Iraq in a case control study which was done on 60 female patients with breast cancer and 60 female patients with benign breast tumor which compared with 75 age, BMI and sex-matched healthy subjects. Blood samples were collected from fasting patients and controls and put into EDTA tube for DNA extraction for subsequent screening of VEGF rs699947 gene polymorphisms by PCR-RFLP method. Results revealed that the incidence of malignant tumor were associated with the genotypic distribution and allelic frequency of VEGF rs699947 gene polymorphisms in that the AA genotype and A allele showed a strong correlation with the risk of malignant breast tumor in comparison with controls. The findings of this study proposed that VEGF rs699947 variant (AA) significantly increased the risk of breast cancer. It was also concluded that A allele is associated with the increased risk of breast cancer. Keywords : breast cancer, rs699947, VEGF